Rituximab-induced autoimmune hepatitis: A case study and literature review

Polymnia Galiatsatos; Sarit Assouline; Adrian Gologan; Nir Hilzenrat

doi:10.3138/canlivj-2020-0009

Rituximab-induced autoimmune hepatitis: A case study and literature review

Polymnia Galiatsatos, Sarit Assouline, Adrian Gologan, Nir Hilzenrat

Research output: Contribution to journal › Article › peer-review

3 Scopus citations

Abstract

Rituximab is a monoclonal antibody to CD20, often used to treat B-cell lymphomas and various autoimmune diseases. While there is extensive literature on rituximab-induced liver injury related to hepatitis B reactivation, there have been no reports to date of autoimmune-type idiopathic drug-induced liver injury from this drug. We present a case of necro-inflammatory hepatitis with autoimmune features in a 40-year-old female after receiving a second dose of rituximab for mucosa-associated lymphoid tissue (MALT) lymphoma, with a review of the literature.

Original language	English
Pages (from-to)	381-386
Number of pages	6
Journal	Canadian Liver Journal
Volume	3
Issue number	4
DOIs	https://doi.org/10.3138/canlivj-2020-0009
State	Published - 1 Jan 2020
Externally published	Yes

Keywords

Autoimmune hepatitis
Drug-induced liver injury
Idiopathic drug-induced liver injury
MALT lymphoma
Necro-inflammatory hepatitis
Rituximab

ASJC Scopus subject areas

Hepatology

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.3138/canlivj-2020-0009

Cite this

@article{ba1a967a9f6b491598183e15732c0888,

title = "Rituximab-induced autoimmune hepatitis: A case study and literature review",

abstract = "Rituximab is a monoclonal antibody to CD20, often used to treat B-cell lymphomas and various autoimmune diseases. While there is extensive literature on rituximab-induced liver injury related to hepatitis B reactivation, there have been no reports to date of autoimmune-type idiopathic drug-induced liver injury from this drug. We present a case of necro-inflammatory hepatitis with autoimmune features in a 40-year-old female after receiving a second dose of rituximab for mucosa-associated lymphoid tissue (MALT) lymphoma, with a review of the literature.",

keywords = "Autoimmune hepatitis, Drug-induced liver injury, Idiopathic drug-induced liver injury, MALT lymphoma, Necro-inflammatory hepatitis, Rituximab",

author = "Polymnia Galiatsatos and Sarit Assouline and Adrian Gologan and Nir Hilzenrat",

year = "2020",

month = jan,

day = "1",

doi = "10.3138/canlivj-2020-0009",

language = "English",

volume = "3",

pages = "381--386",

journal = "Canadian Liver Journal",

issn = "2561-4444",

publisher = "John Wiley and Sons Inc.",

number = "4",

}

TY - JOUR

T1 - Rituximab-induced autoimmune hepatitis

T2 - A case study and literature review

AU - Galiatsatos, Polymnia

AU - Assouline, Sarit

AU - Gologan, Adrian

AU - Hilzenrat, Nir

PY - 2020/1/1

Y1 - 2020/1/1

N2 - Rituximab is a monoclonal antibody to CD20, often used to treat B-cell lymphomas and various autoimmune diseases. While there is extensive literature on rituximab-induced liver injury related to hepatitis B reactivation, there have been no reports to date of autoimmune-type idiopathic drug-induced liver injury from this drug. We present a case of necro-inflammatory hepatitis with autoimmune features in a 40-year-old female after receiving a second dose of rituximab for mucosa-associated lymphoid tissue (MALT) lymphoma, with a review of the literature.

AB - Rituximab is a monoclonal antibody to CD20, often used to treat B-cell lymphomas and various autoimmune diseases. While there is extensive literature on rituximab-induced liver injury related to hepatitis B reactivation, there have been no reports to date of autoimmune-type idiopathic drug-induced liver injury from this drug. We present a case of necro-inflammatory hepatitis with autoimmune features in a 40-year-old female after receiving a second dose of rituximab for mucosa-associated lymphoid tissue (MALT) lymphoma, with a review of the literature.

KW - Autoimmune hepatitis

KW - Drug-induced liver injury

KW - Idiopathic drug-induced liver injury

KW - MALT lymphoma

KW - Necro-inflammatory hepatitis

KW - Rituximab

UR - http://www.scopus.com/inward/record.url?scp=85136745889&partnerID=8YFLogxK

U2 - 10.3138/canlivj-2020-0009

DO - 10.3138/canlivj-2020-0009

M3 - Article

AN - SCOPUS:85136745889

SN - 2561-4444

VL - 3

SP - 381

EP - 386

JO - Canadian Liver Journal

JF - Canadian Liver Journal

IS - 4

ER -

Rituximab-induced autoimmune hepatitis: A case study and literature review

Abstract

Keywords

ASJC Scopus subject areas

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this